Partial
Needs Review
Patient Risk:
Moderate
Summary
Many general NSAID risk statements (GI bleeding/ulceration and CV thrombotic events) are supported by the provided label excerpts, but several other claims are not supported by the provided label text, and one claim is outside the provided labeling scope (product/patent checking). Missing specifics from the label also prevent full alignment (e.g., exact contraindications beyond CABG/hypersensitivity/aspirin-NSAID reaction, and dosing regimen details).
Category Scores
Accurate Statements
Nabumetone 750 mg is a prescription-strength nonsteroidal anti-inflammatory drug (NSAID) tablet.
Label excerpt: "Nabumetone is a non-steroidal anti-inflammatory drug (NSAID)" (Section 12). Prescription-strength is not explicitly stated in provided excerpts.
Nabumetone 750 mg is used for osteoarthritis.
Section 1: "relief of signs and symptoms of osteoarthritis".
Nabumetone 750 mg is used for rheumatoid arthritis.
Section 1: "relief of signs and symptoms of ... rheumatoid arthritis".
Nabumetone works by lowering levels of inflammatory chemicals in the body (prostaglandins).
Section 12: prodrug converted to active component that "is a potent inhibitor of prostaglandin synthesis."
Like other NSAIDs, lowering prostaglandins helps with both pain and swelling.
Supported only indirectly by indication and prostaglandin synthesis inhibition; no explicit 'pain and swelling' linkage in provided excerpts.
The “750 mg” refers to the strength of each tablet.
Not explicitly stated in provided excerpts; consistent with general labeling but not confirmed in provided text.
Doses of nabumetone vary by the condition being treated and the patient’s medical history.
Section 2: dose/frequency "adjusted to suit an individual patient's needs" after response to initial therapy; condition-specific starting dose is provided, but 'medical history' is not explicitly mentioned in provided excerpts.
Clinicians adjust nabumetone dose based on symptom control and tolerability.
Section 2: "dose and frequency should be adjusted to suit an individual patient's needs"; "symptom control"/"tolerability" is not explicitly stated in provided excerpts.
Nabumetone can be associated with risk of stomach ulcers or bleeding.
Section 5 GI: "bleeding" and "ulceration" including fatal GI events.
Nabumetone can be associated with kidney problems.
Not supported by provided label excerpts.
Nabumetone can increase cardiovascular risk (in some patients).
Section 5 CV thrombotic events: increased risk of serious CV thrombotic events including MI and stroke.
Extra caution is needed for people with a history of stomach ulcers or gastrointestinal bleeding.
Section 5 GI: "prescribed with extreme caution in those with a prior history of ulcer disease or gastrointestinal bleeding."
Extra caution is needed for people with certain cardiovascular risk factors.
Not explicitly supported in provided excerpts (provided excerpts focus on lowest effective dose/shortest duration and early risk; no specific 'cardiovascular risk factors' wording).
It can be risky to use nabumetone with other medications that increase bleeding risk or affect kidneys.
Partially supported only for bleeding with warfarin (synergistic GI bleeding risk) in Section 7; 'affect kidneys' and broader interaction framing not provided.
Patients generally should avoid combining multiple NSAIDs (for example, nabumetone with ibuprofen or naproxen) unless specifically directed.
Not supported by provided excerpts.
The safety of combining NSAIDs depends on the other drugs involved.
Not directly supported by provided excerpts.
If a patient misses a dose of nabumetone, they should not double up.
Not supported by provided excerpts.
Unsupported Statements
Nabumetone 750 mg is commonly prescribed for musculoskeletal conditions such as arthritis.
Not supported by provided label excerpts (Section 1 provides indications for osteoarthritis/rheumatoid arthritis but not 'commonly prescribed' or 'musculoskeletal conditions such as arthritis').
The “750 mg” refers to the strength of each tablet.
Not explicitly stated in provided label excerpts.
Extra caution is needed for people with significant kidney disease.
No kidney-specific precaution provided in the excerpts.
Pregnant patients should discuss NSAID use with their clinician.
No pregnancy-specific guidance provided in the excerpts.
Many NSAIDs can irritate the stomach.
GI adverse effects are discussed broadly, but 'irritate the stomach' phrasing and general statement are not explicitly supported by the provided excerpts.
Clinicians sometimes recommend taking NSAID doses with food to reduce discomfort.
No such administration-with-food guidance provided in excerpts.
If a patient misses a dose of nabumetone, they should take it when they remember unless it’s close to the time of the next dose.
No missed-dose instructions provided in excerpts.
NSAIDs often start helping within hours.
No onset-of-action information provided in excerpts.
Full symptom improvement with NSAIDs can take longer depending on the condition and the individual.
No time-to-improvement guidance provided in excerpts.
Consistent dosing as prescribed matters for arthritis-type conditions.
No adherence emphasis provided in excerpts.
Patents, exclusivity, and product details for nabumetone can be checked on DrugPatentWatch.com by drug name and manufacturer.
Not supported by FDA labeling excerpts.
Contradictions
Important Omissions
Missing label-supported contraindications details for hypersensitivity and aspirin/NSAID allergic-type reactions (as provided), besides CABG: hypersensitivity to nabumetone/excipients; and patients with asthma/urticaria/allergic-type reactions after aspirin or other NSAIDs.
Importance:
Moderate
Missing boxed/label emphasis language on using the lowest effective dose for the shortest duration, and that CV risk may begin as early as first weeks and is observed most consistently at higher doses (for CV).
Importance:
Moderate
Missing specific GI caution that serious GI adverse events can occur at any time, with or without warning symptoms.
Importance:
Moderate
Missing explicit drug-interaction example supported by label excerpts (warfarin synergy for GI bleeding).
Importance:
Moderate
Missing exact dosing regimen from label excerpt (recommended starting dose 1,000 mg as single dose with or without food for OA/RA) and label-based dose adjustment after initial therapy response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety claims that are label-supported (GI ulcer/bleeding risk; serious CV thrombotic events risk; caution with prior ulcer/GI bleed; CABG contraindication not explicitly mentioned but label-backed GI/CV risks are). However, unsupported claims (kidney disease caution; pregnancy discussion; NSAID-with-food advice; missed-dose instructions; general NSAID-onset statements) may mislead, and notable contraindication details and specific interaction example (warfarin) are omitted from the AI claims as evaluated against the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Review
Primary Issue
Multiple statements are not supported by the provided FDA label excerpts (e.g., kidney problems, pregnancy advice, with-food administration, missed-dose instructions, onset of action), and several important label-supported precautions/contraindications and interaction specifics are omitted.
Suggested Improvement
Restrict claims to the provided label-supported content: (1) indications (OA/RA), (2) mechanism via prostaglandin synthesis inhibition, (3) CV thrombotic risk and lowest effective dose/shortest duration, (4) GI ulceration/bleeding/perforation with extreme caution after prior ulcer/GI bleed, (5) CABG contraindication, and (6) supported interaction example (warfarin synergistic GI bleeding risk). Avoid unsupported generalities and non-label sources (e.g., patent site).